Phase 3 N=59 Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Buoy Electrolyte Study on Hydration Status of Active Men and Women
Dehydration · Electrolyte Imbalance · Electrolyte Depletion
Primary: Net Fluid Balance — 0.28; 0.05; 0.03 Liter
N/A N=240 POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
Phase 4 N=52 Early Sodium Intake in Preterm Newborns
Hyponatremia · Premature
Primary: Hyponatremia — 6; 1 Participants — p=0.71
N/A N=61 Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
Hypertension
Primary: Change in Fasting Plasma Glucose From Week 4 to Week 16 — -5.6; 2.3 mg/dL
N/A N=19 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A
End Stage Renal Disease
Primary: Adherence With Proposed Interventions — 88; 90; 83; 80 Percentage of sessions
N/A N=23 Variation in Urine Electrolytes, pH and Specific Gravity Throughout the Day
Healthy
Primary: Citrate/Creatinine Ratio — 0.658644; 0.584115; 0.562886; 0.540394 ratio
Phase 2 N=30 Fluid Chloride and AKI in Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Change in [TIMP2]*[IGFBP7] Biomarker — 0.015; 0.009 (ng/mL)^2/1000
N/A N=974 Isotonic Solution Administration Logistical Testing
Acute Kidney Injury
Primary: Proportion of Isotonic Crystalloid Which is 0.9% Saline — 91.2; 21.0 Percentage of fluid that was saline — p=0.001
N/A N=23 Aldosterone and Glucose Homeostasis
Diabetes Mellitus
Primary: Insulin Secretion — 48.9; 37.6; 51.8; 34.4 uU/mL
Phase 3 N=161 Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia
Hyponatremia
Primary: Hospital Acquired Hyponatremia — 10; 11; 1 participants
Phase 3 N=78 Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children
Hyponatremia
Primary: Change in Sodium Levels — 139.9; 138.1; 138.1; 138.2 mEq/L — p=0.030
Early Phase 1 N=40 Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure
Heart Failure
Primary: Change in Blood Volume — -320; -447 mL — p=0.56
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
Phase 2 N=29 The Effects of Potassium on Glucose Metabolism in African Americans
Borderline Hypokalemia
Primary: Change in Glucose Tolerance as Measured by Area-under-the-curve — 328; 1000 AUC - mg*min/dL — p=0.5582
Phase 3 N=167 Maintenance Intravenous Fluids in Children
Hyponatremia
Primary: Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L) — 1; 2; 8 participants — p=<0.05
Phase 3 N=149 Alkali Therapy in Chronic Kidney Disease
Chronic Kidney Disease · Metabolic Acidosis
Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds
Phase 4 N=83 The Effects of Potassium Citrate on Bone Metabolism
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
Phase 4 N=10 Effect of Licorice and Hydrochlorothiazide on Plasma Potassium
Hypokalemia
Primary: Plasma Potassium — 4.0; 4.0; 4.1; 3.7 mmol/l — p=0.007
Phase 4 N=43 Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Kidney Failure, Chronic
Primary: Efficacy of Patiromer in Reducing Serum Potassium — 6.17; 6.6; 5.9; 6.47 mEq/L
Phase 4 N=30 Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Hypertension
Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg
N/A N=171 Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults
Osteoporosis · Sarcopenia
Primary: Biochemical Markers of Bone Turnover — -6.25; -3.36; -0.14; 0.5 nmol/mmol
Phase 4 N=34 Effect of Coconut Water on Hydration Status in Pediatric Population
Sports Nutrition
Primary: To Determine the Effect of AC vs EO on Hydration Status in Adolescents Who Perform Physical Exercise of Aerobic Competition. — 53; 36; 15; 32 Number participants…
Phase 2 N=27 The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
ESRD · Hyperkalemia · End Stage Renal Disease
Primary: Adverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by…
Phase 3 N=258 Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial
Hyponatremia · Hypernatremia
Primary: Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
N/A N=5,381 Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit
Critical Illness · Acute Kidney Injury
Primary: Major Adverse Kidney Event Within 30 Days — 659; 615 Participants — p=<0.05
Phase 4 N=16 Effect of Aldosterone on Energy Starvation in Heart Failure
Heart Failure · Nonischemic Dilated Cardiomyopathy
Primary: Left Ventricular Work-metabolic Index (WMI) at Baseline — 7.4 (x10^6), mL x mm Hg/m^2
Phase 3 N=754 Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
Hyperkalemia
Primary: Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment. — -0.00128; -0.00187; -0.00205; -0.00280 log(mmol/L)/hour
Phase 4 N=157 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation
Fluid Loss · Symptom Complex, Triple · Emergencies
Primary: Quality of Recovery-40 Score at 24 Hours — 166.8; 164.4 units on a scale — p=0.608